# Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

> **NCT01035437** · NA · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Esophageal Neoplasm

## Interventions

- **DRUG:** HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)

## Key facts

- **NCT ID:** NCT01035437
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no accrual
- **Last updated:** 2012-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035437, "Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01035437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*